A 65-year-old cisgender man with HIV presents for a routine follow-up visit. He has done very well on an antiretroviral regimen of dolutegravir plus tenofovir alafenamide-emtricitabine. Four years ago, he had a dual-energy X-ray absorptiometry (DXA) scan that demonstrated osteoporosis at the hip and spine. At that time, the medication tenofovir DF-emtricitabine was changed to tenofovir alafenamide-emtricitabine.
Which one of the following statements is TRUE about bone mineral density and individuals with HIV compared to persons without HIV?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 26th, 2023
September 26th, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5